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Abstract
Cerebral rates of anaplerosis are known to be significant, yet
the rates measured in vivo have been debated. In order to
track glutamate metabolism in brain glutamatergic neurons
and brain glia, for the first time unrestrained awake rats were
continuously infused with a combination of H14CO3
– and
[1)13C]glucose in over 50 infusions ranging from 5 to 60 min.
In whole-brain extracts from these animals, the appearance of
14C in brain glutamate and glutamine and appearance of 13C
in the C-4 position of glutamate and glutamine were measured
as a function of time. The rate of total neuronal glutamate
turnover, the anaplerotic rate of synthesis of glutamine and
glutamate from H14CO3
–, flux through the glutamate/gluta-
mine cycle, and a minimum estimate of whole-brain anaple-
rosis was obtained. The rate of synthesis of 14C-glutamate
from H14CO3
– was 1.29 ± 0.11 nmoles/min/mg protein,
whereas the rate of synthesis of 14C-glutamine was
1.48 ± 0.10 nmoles/min/mg protein compared to total
glutamate turnover of 9.39 ± 0.73 nmoles/min/mg protein.
From the turnover rate of glutamine, an upper limit for flux
through the glutamate/glutamine cycle was estimated at
4.6 nmoles/min/mg protein. Synthesis of glutamine from
H14CO3
– was substantial, amounting to 32% of the glutamate/
glutamine cycle. These rates were not significantly affected by
a single injection of 100 mg/kg of the antiepileptic drug gab-
apentin. In contrast, acute administration of gabapentin sig-
nificantly lowered incorporation of H14CO3
– into glutamate and
glutamine in excised rat retinas, suggesting metabolic effects
of gabapentin may require chronic treatment and/or are
restricted to brain areas enriched in target enzymes such as
the cytosolic branched chain aminotransferase. We conclude
that the brain has a high anaplerotic activity and that the
combination of two tracers with different precursors affords
unique insights into the compartmentation of cerebral meta-
bolism.
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Glutamate (along with aspartate) is the major excitatory
neurotransmitter in the mammalian brain (Fonnum 1984;
Takahashi et al. 1997). This amino acid is unusual, because it
has a dual role, ﬁrst as a neurotransmitter and, second, as an
important intermediate of nitrogen metabolism (LaNoue and
Tischler 1974; Schoolwerth et al. 1977; Strzelecki et al.
1988; Sterniczuk et al. 1991; Sonnewald et al. 1993). Its role
as an intermediate in nitrogen metabolism and in energy
production in peripheral tissues is well recognized, but the
relationship between its metabolism and its neurotransmitter
function has received less attention.
Glutamate in its role as neurotransmitter is released from
nerve endings of glutamatergic nerves (Torgner and Kvamme
1990) and from photoreceptor cells in the retina (Mimura
et al. 2002). It signals to post-receptor neurons via various
subclasses of glutamate receptors (Michaelis 1998). To clear
it from the synaptic space, stop the signal, and to prevent
neurotoxicity due to continued signaling, glutamate is rapidly
transported into astrocytes that surround the glutamatergic
synapses (Shousboe et al. 1993; Rothstein et al. 1994;
Chaudhry et al. 1995; Derouiche 1996). Glutamate trans-
porters in these astrocytes use the plasma membrane Na+
Received March 10, 2004; revised manuscript received April 19, 2004;
accepted April 20, 2004.
Address correspondence and reprint requests to Kathryn F. LaNoue,
Cellular and Molecular Physiology, 500 University Drive, H166, Hers-
hey, PA 17033, USA. E-mail: klanoue@psu.edu
Abbreviations used: BCATc and BCATm, branched chain amino-
transferases; i.p., intraperitoneal.
Journal of Neurochemistry, 2004, 90, 1104–1116 doi:10.1111/j.1471-4159.2004.02576.x
1104  2004 International Society for Neurochemistry, J. Neurochem. (2004) 90, 1104–1116
gradient as a source of energy to maintain high glutamate
gradients (in/out) across the glial plasma membrane (Kanai
et al. 1993). To return the glutamate carbon skeleton to the
neurons, glutamate is converted to glutamine via ATP-
dependent glutamine synthetase, exclusively expressed in the
astrocyte cytosol (Martinez-Hernandez et al. 1977; Berl and
Clarke 1983). Glutamine leaves the astrocytes and is taken
up by neurons where glutaminase regenerates glutamate,
which completes the well-known glutamate/glutamine cycle
(Shank et al. 1985; Shousboe et al. 1993). As originally
formulated, the glutamate/glutamine cycle hypothesis (van
den Berg and Garﬁnkel 1971; Benjamin and Quastel 1974;
Shank et al. 1985; Cooper and Plum 1987) provided an
explanation for previous data (Berl et al. 1962, 1970, 1978)
demonstrating that glutamate in the brain is highly compart-
mentalized and that a small, rapidly turning over compart-
ment synthesizes glutamine from glutamate.
For some years, after the existence of the cycle was
veriﬁed, glutamate’s role as an intermediary metabolite in the
brain was largely ignored. It was assumed that after entry into
the glia from the neurons it was stochiometrically converted
to glutamine, possibly after equilibration with a-ketogluta-
rate. However, when glutamate exchanges its a-amino
nitrogen to become a-ketoglutarate it is likely to be
consumed in the citric acid cycle. Glutamate is the substrate
of numerous transaminases and donates its nitrogen to a-keto
acids to form most other dispensable amino acids (Strzelecki
et al. 1988; Sterniczuk et al. 1991; Sonnewald et al. 1993).
Similarly a-ketoglutarate is the major a-keto acid acceptor in
the breakdown of amino acids. Thus, in the brain, glutamate
is obligatorily involved in amino acid synthesis and degra-
dation as well as in neurotransmission. Neurons experience a
constant loss of glutamate via neurotransmission. If gluta-
mate were not returned to neurons rapidly enough, the loss
would be compensated by conversion of neuronal a-
ketoglutarate to glutamate but the neuronal citric acid cycle
would be depleted of cycle intermediates and ATP synthesis
would stop. On the other hand, astrocytes experience a
steady inﬂux of glutamate carbon from glutamatergic
neurotransmission. The glutamate may be converted to a-
ketoglutarate, potentially increasing the supply of citric acid
cycle intermediates. Too rapid oxidation of glutamate via a-
ketoglutarate in the astrocytic compartment could compro-
mise the supply of glutamine to the neurons and possibly
slow neuronal ATP synthesis. Too little oxidation might
produce an excess of astrocytic glutamate and impair
transport of glutamate into the astrocytes from the synaptic
space. It is therefore important to understand how the level of
a-ketoglutarate and other citric acid cycle intermediates are
regulated and maintained.
The presence of such regulatory mechanisms is supported
by the observation that all enzymes required are expressed in
astrocytes (Patel 1989; Schmoll et al. 1995; Cruz et al.
1998). To prevent an overaccumulation of a-ketoglutarate,
astrocytes express enzymes that can decarboxylate the citric
acid cycle intermediates from 4-carbon to 3-carbon interme-
diates forming pyruvate from glutamate (Sonnewald et al.
1993; Hutson et al. 1998). These enzymes include malic
enzyme and phosphoenolpyruvate carboxykinase. There is
some controversy about whether neurons also express malic
enzyme (Vogel et al. 1998; McKenna et al. 2000). Synthesis
of new citric acid cycle intermediates from bicarbonate and
pyruvate is accomplished by the mitochondrial enzyme
pyruvate carboxylase, exclusively expressed in astrocytes in
adult brain (Shank et al. 1985; Patel 1989). Together, these
astrocytic anaplerotic (pyruvate carboxylase) and counter-
anaplerotic enzymes (e.g. malic enzyme) constitute a pyru-
vate/malate cycle in the brain, also referred to as pyruvate
cycling (Cerdan et al. 1990; Cruz et al. 1998). Studies
described in this paper were designed to estimate ﬂuxes
through the pyruvate/malate cycle.
Because of the high degree of compartmentalization of the
cycle and the complexity of the brain, it has been difﬁcult to
understand how the pyruvate/malate cycle is regulated and
whether it is capable of inﬂuencing neurotransmission or
neurodegeneration due to excess glutamate. In the present
study, we have conducted a full kinetic analysis using
methods involving both 14C (entry of label via anaplerosis in
astrocytes) and 13C (entry of label via glucose in neurons) to
get an accurate value for brain glutamate turnover in vivo in
awake animals. In awake rats, the present study demonstrates
that anaplerosis provides a substantial fraction of the
glutamine synthesized in the astrocytes. We further used
this approach to test whether acute administration of
gabapentin inhibits global brain de novo glutamate synthesis
in vivo. Gabapentin is a neuroactive drug used clinically to
treat epilepsy (Bergey et al. 1997) and chronic pain (Row-
botham et al. 1998), and we have shown that this leucine
analog inhibits de novo (anaplerotic) glutamate synthesis
from H14CO3
– in rat retinas (Hutson et al. 2001; LaNoue
et al. 2001; Lieth et al. 2001).
Materials and methods
Experimental animals
Male Sprague–Dawley rats (244 ± 18 g, Harlan, Madison, WI,
USA) were used for whole animal in vivo perfusions. The perfusions
were done at Wake Forest University School of Medicine. These rats
were housed under a 12-h light/dark cycle and allowed free access to
food and water. After surgery, a liquid diet was provided (Bio-Serv,
Frenchtown, NJ, USA; product no. F1259SP) instead of the standard
chow diet. The study protocol was approved by the Institutional
Review Committee (IRC) of the Wake Forest University School of
Medicine. Animals were treated in accordance with the guidelines
published in the NIH Guide for the Care and Use of Laboratory
Animals. Sprague–Dawley rats were used as a source of excised
retinas for ex vivo studies. The rats were exposed to a 12-h light/dark
cycle and had free access to food and water. The ex vivo retinal
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study protocol, which was carried out at Penn State, was approved
by the IRC at the Penn State University College of Medicine.
Chemicals
The neuroactive drug gabapentin (neurontin) was a gift from Parke-
Davis Pharmaceutical Research Division of Warner-Lambert Co.,
(Ann Arbor, MI, USA). Radioactive sodium 14C-bicarbonate (NEC-
086H) was purchased from NEN Life Science Products, Inc.
(Boston, MA, USA). D-[1)13C]glucose was purchased from
Cambridge Isotope (CLM-420; Andover, MA, USA). Enzymes for
metabolic analyses were purchased from Sigma Aldrich or Roche
Molecular Biochemicals (Indianapolis, IN, USA).
Experimental procedure for in vivo brain studies
For in vivo studies, rats were anesthetized with intraperitoneal (i.p.)
Nembutal (75 mg/kg body weight) and sterile surgery performed to
implant catheters in the carotid artery and jugular vein as described
by Crist et al. (1998). The animals were allowed to recover from
surgery for 48–72 h and had free access to a liquid diet. On the day of
the experiment rats were placed in a metabolic cage with an air ﬂow
inlet and outlet. The outlet air was passed through a column of NaOH
pellets to trap 14CO2
–. The metabolic cage was located within a fume
hood. The catheters emerged from the rats attached to a swivel
apparatus at the back of the rats’ necks. Isotopes were infused
through the venous catheter and blood samples taken from the carotid
artery catheter. Gabapentin (100 mg/kg) or saline was administered
i.p. 30 min prior to the start of the glucose and bicarbonate infusion.
The infusion medium consisted of 1 mCi sodium 14C-bicarbonate, 1
mmole 100% enriched [1)13C]glucose, and 0.1 mmole NaCl per ml
sterile H2O. A priming dose of the infusion medium (0.5 mL) was
followed immediately by a steady infusion (1 mL/h) lasting from 5 to
60 min. During the infusion, blood samples were taken from the
carotid artery at 5, 10, 20, 40, and 60 min after the priming dose.
Acid volatile (H14CO3
–) radioactivity in the blood was determined as
well as glucose 13C fractional enrichment in these blood samples.
Serum pH, HCO3
–, and pCO2 was measured in parallel experiments
to estimate venous HCO3
– speciﬁc activity. Incorporation of 14C
from H14CO3
– into serum glucose due to hepatic gluconeogenesis
was assessed to be small, because these fed rats exhibit low rates of
hepatic gluconeogenesis. The average speciﬁc radioactivity of serum
glucose was 10 dpm/nmol compared to a value of 113 ± 4 dpm/
nmol for serum H14CO3
–. The blood glucose concentration varied
from 5 to 8 mM.
The priming dose and continuous infusion of H14CO3
– into the
jugular vein kept the speciﬁc activity of H14CO3
– constant with time
in individual rats, though the value varied among animals. Infusion
of [1)13C]glucose resulted in an average isotopic 13C-enrichment
for serum glucose of 0.541 ± 0.013, n ¼ 31. The injection of
gabapentin into the experimental animals prior to the steady-state
infusions did not change this 13C enrichment value signiﬁcantly.
At the end of the infusion, the rats were decapitated and their
heads dropped immediately into liquid nitrogen. The frozen brain
tissue was removed from the skull, and the cerebellum was
separated from the other brain tissue. The tissue (whole brain minus
cerebellum) was then extracted with 6% perchloric acid and
neutralized with KOH. Enzymatic assays of glucose, lactate,
a-ketoglutarate, glutamate, and glutamine were performed by
standard procedures (Bergmeyer 1965; Williamson and Corkey
1969), and ion exchange chromatography (Gamberino et al. 1997)
was used to separate metabolites. On average, each extract contained
about 950 mg wet weight of tissue and 70 mg protein, which
amounts to a 7.5% protein content of the wet brain.
The data are presented as nmoles of metabolite/mg protein. The
time averaged serum H14CO3
– speciﬁc radioactivity, separately
determined for each animal, was used to calculate the nmoles of
H14CO3
– incorporated into each brain metabolite, reported as
nmoles H14CO3
– incorporated/mg protein. Protein was determined
by the Bradford (1976) procedure after diluting and solubilizing the
perchloric acid brain extract protein pellet with 1 M NaOH.
Experimental procedure for ex vivo retinal studies
Retinas were surgically removed from anesthetized rats as described
previously (Lieth et al. 2001). Half retinas minus pigment epithe-
lium were placed immediately in 1 mL Krebs bicarbonate buffer
containing 5 mM glucose, 0.2 mM pyruvate, and 0.03 mM NH4Cl.
The medium was equilibrated with 5% CO2, 95% O2 at 37C,
pH 7.4. Gabapentin (1 mM) was included in one half of the
incubations. After a 3-min equilibration period, 150 lCi of H14CO3
–
was added, the vessels were sealed to maintain H14CO3
– levels, and
incubations proceeded for 20 min. We have shown previously that
20 min is sufﬁcient to allow the intermediate metabolites to come to
isotopic equilibrium (Lieth et al. 2001). At t ¼ 20 min, retinas were
removed from the radiolabeled medium and placed in fresh media
identical to the ﬁrst but lacking the 14C, resulting in a pulse-chase
experiment. Samples were taken at 4 min intervals during the chase
period, including t ¼ 0 to follow the decline of 14C in glutamate,
glutamine, lactate, and aspartate. At these time points, retinas were
removed from the medium, rinsed, and placed in 2% perchloric acid.
All samples were neutralized with KOH. The decline of speciﬁc
activity of intraretinal glutamate with time followed ﬁrst-order
kinetics, allowing calculations of the turnover of these metabolites
as well as ﬂux through the glutamate/glutamine cycle as described
previously (Lieth et al. 2001).
Chromatography and enzyme analyses
The total radioactivity in each neutralized brain or retinal extract
was determined by counting a small aliquot of each sample in a
Beckman scintillation counter. For the brain extracts, aliquots
containing the equivalent of 45 mg of brain protein were placed
on Dowex-1 acetate ion exchange columns, and fractions collected
as described previously using a step gradient of acetic acid
(Gamberino et al. 1997). Metabolite peaks were pooled and total
14C determined for each metabolite (glucose, glutamine, glutam-
ate, asparate, and lactate). Glucose was separated from glutamine
in the neutral fraction by conversion to glucose-6-phosphate as
described previously (Lieth et al. 2001). On average, 88% of the
radioactivity in each sample was identiﬁed as speciﬁc metabolites.
Previous studies (Lieth et al. 2001) indicated that the remaining
counts are citric acid cycle intermediates. The remainder of the
unfractionated, neutralized, protein-free brain extract was used to
measure the mass amount of glutamate, glutamine, aspartate, and
a-ketoglutarate using standard techniques of spectrophotometric
enzymatic analysis (Bergmeyer 1965; Williamson and Corkey
1969). In the case of retinas, half of each sample was subjected to
Dowex-1 chromatography to separate the 14C-labeled metabolites
(Gamberino et al. 1997) and the other half was used for
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enzymatic assays. No 13C analyses were carried out in retinal
samples.
NMR analysis
The pooled fractions of each metabolite were lyophilized. The dry
samples were sent to University of Minnesota where they were
reconstituted in 0.35 mL aqueous medium containing 99% enriched
13C-formate and used for 13C analysis by NMR. Recovery was 85–
95% and the measured recovery values were used to correct ﬁnal data.
13C NMR spectra were acquired using a 600 MHz Varian Unity
INOVA spectrometer and a pulse-acquire sequence under fully
relaxed conditions (45 pulse angle, repetition time TR ¼ 2 · T1,
based on the longest experimentally determined T1 of the resonances
investigated). WALTZ-16 was used for NOE generation during the
relaxation delay and for decoupling during acquisition. The concen-
tration of 13C-labeled metabolites was determined by integration of
peak areas corrected for NOE effects relative to a known concentra-
tion of 99% enriched 13C-formate included in the samples. Isotopic
enrichments were determined based on enzymatically measured total
tissue concentrations and by isotopomer analysis at 60 min.
The serum glucose 13C isotopic enrichments were determined by
1H-NMR spectroscopy at 600 MHz based on the 1H resonance
bound to C-1 of a-glucose at 5.24 ppm. The coupling between 13C
and 1H gives rise to a doublet peak and the isotopic enrichment can
be obtained from the ratio of the integral of this doublet to the whole
area of the resonance. The spectra were acquired under fully relaxed
conditions after reconstituting the samples in 100% D2O.
Methods for calculating rates
The steady-state kinetic method and equations used to calculate
glutamate turnover, glutamate/glutamine cycle ﬂux, and the rate of
anaplerotic synthesis of glutamate have been described previously
(Lieth et al. 2001). The 13C labeling of glutamate was used to
calculate glutamate C-4 turnover using the following expression (1),
based on the derivation reproduced in the Appendix:
dð13Glu14 13 Glu4ðtÞÞ
dt
¼ kAð13Glu14 13 Glu4ðtÞÞ ð1Þ
If A is the mass amount of glutamate (pool size), then 13Glu14 /A is
the enrichment of the C-4 of glutamate at steady-state, 13Glu4(t) is
the time course of label incorporation of the C-4 of glutamate to
isotopic steady state. The symbol kA is the ﬁrst-order rate constant
of the approach to steady state and t is the elapsed time from start of
13C-glucose infusion. Brieﬂy, the ﬁrst-order rate constant of
glutamate synthesis from [1)13C]glucose was measured by plotting
the ﬁrst-order approach of the percentage 13C-enrichment of the
C-4 of glutamate to a steady-state value. The percentage 13C-
enrichment was plotted as a function of time and reiterative curve
ﬁtting on all experimental points carried out to estimate the rate
constant kA and the
13C steady-state value (C). The value kA,
multiplied by the mass of glutamate, A, represents the calculated
apparent rate of glutamate breakdown, Vout ¼ kAA, which at steady
state is equal to its rate of appearance. The kA also provides an
estimate of the turnover time corresponding to the half-life of any
isotopic label in total brain glutamate.
To estimate the amount of H14CO3
– incorporated into glutamate,
the dpm of 14C-label in glutamate at steady state was divided by the
speciﬁc activity of H14CO3
– (dpm/nmol) resulting in nmoles
H14CO3
– in glutamate/mg protein. This value was multiplied by 2,
because in the present study it was assumed that only half of each
H14CO3
– incorporated into oxaloacetate by pyruvate carboxylase
reaches a-ketoglutarate (Lieth et al. 2001). Thus, the corrected
amount of H14CO3
– incorporated into glutamate at steady state (A*)
can be used to estimate the rate of synthesis of glutamate from
H14CO3
– when multiplied by the glutamate turnover rate constant,
i.e. by kA. The rate constant kA was determined as described above.
The vast majority of brain glutamate is neuronal, whereas
anaplerosis occurs in glia. Therefore, glutamine labeled ﬁrst by
H14CO3
– in astrocytes must be considered the precursor of neuronal
14C-glutamate via the enzyme reaction catalyzed by glutaminase
(see Appendix). To estimate the rate constant, kB, the turnover rate
constant of glutamine, we measured the ﬁrst-order approach of 14C-
glutamine to steady state using equations similar to (1) (as done for
[4)13C]glutamate above and see Results). If the turnover rate
constant of glutamine, kB, is assumed to reﬂect glutamine turnover
and if B* is the nmoles of H14CO3
– incorporated into glutamine at
steady state, then kBB* is the rate of synthesis of glutamine from
H14CO3
–. Multiplying kB by the glutamine mass per mg brain
protein (B), the product kBB approximates the overall rate of
glutaminase at steady state, which in this study was assumed to be
equal to the rate of the glutamate/glutamine cycle. As noted above,
the calculated value for glutamine ﬂux assumes all 14CO2 ﬁxation
occurs in astrocytes. If some 14CO2 ﬁxation occurs in neurons, either
by exchange or by net ﬁxation through reversible malic enzyme,
then the calculated rate will be overestimated.
Rates of H14CO3
– incorporation into glutamate and glutamine in
excised, ex vivo rat retinas were determined as described previously
(Lieth et al. 2001). Brieﬂy, half retinas were incubated for 20 min at
37C in Krebs Ringer bicarbonate medium containing H14CO3–
(25 mM, 150 lCi/mL). When the retinas reached steady state with
respect to the 14C-speciﬁc activities of glutamate and glutamine, they
were transferred to fresh medium with no 14C. Retinas were removed
from the washout medium at 4-min intervals and the ﬁrst-order rate
constant of glutamate washout determined. The ﬁrst-order rate
constant is also the turnover constant kA and can be used to calculate
ﬂuxes. In this case A* is the steady-state 14C label in glutamate
observed at the end of the ﬁrst incubation. B* is the steady-state 14C
label in glutamine. The assumption is made that kBB* ¼ kAA*.
Statistics
Analytic values were compared by t-tests. For rate constants,
variation and conﬁdence limits were assessed by regression analysis.
In the case of the retinal kinetics, because each rat had four half
retinas, and four time points were used for 14C washout curves, a
rate constant could be assigned to individual rats and then these
values used to obtain means and SEM.
Results
Comparison of the rates of changes in 14C-specific
activities and 13C-enrichment in whole-brain glutamate
and glutamine
To calculate speciﬁc activities of 14C-glutamate and 14C-
glutamine, the 14C in the glutamate and glutamine
chromatographic peaks (in dpm/mg) were divided by the
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enzymatically measured amounts of glutamate and gluta-
mine (mass amounts in nmoles/mg protein) and this
speciﬁc activity was divided by the H14CO3
–-speciﬁc
activity. This provides a value (nmoles H14CO3
– incorpor-
ated/nmol amino acid) that is independent of assayed
protein. The same was done for 13C-enrichments which are
also independent of measured protein. Enrichment is the
percentage of 13C in the total carbon (13C, 12C, and 14C)
of the amino acid. Provided that most H14CO3
– is
converted to citric acid cycle intermediates in the glial
compartment (the site of glutamine synthesis), the speciﬁc
activity of glutamine is expected to be higher than that of
glutamate. Most of the glutamate in the brain is neuronal
and thus 14C-labeled glutamate must be synthesized mainly
from 14C-glutamine exported from the glia. Synthesis of
neuronal glutamate from glucose dilutes the 14C entering
the neuronal pool from 14C-glutamine. Indeed, the 14C-
speciﬁc activity of glutamine was 2.3 times higher than
that of glutamate at isotopic steady state (Fig. 1).
The [4)13C]glutamate in the neuronal and glial pool was
the result of metabolism of the infused [1)13C]glucose and
was much less diluted than the 14C by the intervening citric
acid cycle intermediates (Fig. 1). The rate of incorporation
and the steady-state values of 13C-enrichment were similar
for glutamate and glutamine. The steady-state enrichment
was approximately 0.5 times that of 13C-glucose enrichment
as only half the pyruvate reaching brain mitochondria is
labeled by the [1)13C]glucose.
Gabapentin did not lower rates of incorporation of 14C or
13C into glutamate or glutamine (Fig. 1).
Turnover of brain glutamate
To determine the ﬁrst-order rate constant of glutamate
turnover we analyzed the kinetics of the approach of
[4)13C]glutamate to steady state. We assumed that the
[4)13C]glutamate signal was dominated by a single neuronal
glutamate pool which approached a steady value of 13C
enrichment as a ﬁrst-order function. Fitting the solution of (1)
(see Methods) to the experimental data provided a good ﬁt
with kA equal to 0.066/min (Fig. 2). Individual data points
were used for the curve ﬁtting, but only means and standard
errors of the means are shown in Fig. 2. Judging from the
glutamate concentration (A) and the turnover rate constant
(kA ¼ 0.066/min), the turnover of glutamate (kAA ¼
9.4 ± 0.7 nmoles/min/mg protein) was not altered statisti-
cally due to the presence of gabapentin (Table 1).
Knowing the ﬁrst-order rate constant of glutamate turn-
over, it is also possible to calculate the rate of synthesis of
glutamate from H14CO3
–. The ﬁrst-order rate constant
applies to the whole glutamate pool and any isotopic fraction
of that pool. A* is the nmoles of H14CO3
– incorporated into
the total glutamate pool per mg of protein at steady state.
Multiplying steady-state 14C-glutamate speciﬁc activity
(Fig. 1) by the mass of glutamate per mg of protein, provides
the value for A* ¼ 10.60 ± 0.05 nmoles H14CO3–/mg of
protein in the glutamate pool. The calculated rate of synthesis
is equal to 2 · kAA* ¼ 1.4 ± 0.1 nmoles H14CO3–/min/mg
protein, which is 15% of the turnover of glutamate.
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Fig. 1 Time course of 14C-specific activity and 13C enrichment of brain
glutamine and glutamate. Awake rats were perfused intravenously
simultaneously with H14CO3
– and [1)13C]glucose. Some rats (c and d)
were injected intraperitoneally with 100 mg/kg gabapentin prior to the
start of perfusion. Times shown are elapsed time after start of isotope
infusion. Glutamate (m) and glutamine (d) were isolated from neut-
ralized perchloric extracts of brain tissue. (a) and (c) provide values for
14C-specific activity, and (b) and (d), 13C enrichment of glutamate and
glutamine. Values shown are means ± SEM.
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Therefore the percentage of the total glutamate pool provided
by the anaplerotic pathway is 15%.
Turnover of brain glutamine
The ﬁrst-order rate constant of glutamine turnover (kB) and
the steady-state value of 14C-glutamine (B*, the nmoles
H14CO3
–/mg protein in glutamine) were estimated from
changes in 14C-glutamine (Fig. 3). Reiterative trials of (1)
matching the changes of 14C-glutamine with time, using
0.084/min as the ﬁrst-order rate constant provides the best
match of the data to the theoretical curve (Fig. 3). To obtain
the rate of disappearance of 14C-glutamine in control rats, kB
was multiplied by the steady-state value of 14C-glutamine
(B* ¼ 8.80 ± 0.06 nmoles/min/mg) and by 2, resulting in
2 kBB* ¼ 1.48 ± 0.17 nmoles/min/mg protein. The rate of
synthesis of radiolabeled glutamate, 2 kAA* (Fig. 2) was
1.29 ± 0.11 nmoles/min/mg protein. The observation that
14C-glutamate synthesis is slightly lower than glutamine
breakdown is consistent with the possibility that some 14C-
glutamine is lost from the glial compartment and may exit the
brain. The fact that 14C-glutamine synthesis only slightly
exceeded 14C-glutamate synthesis suggests that little anaple-
rosis takes place in neurons.
The glutamate/glutamine cycle ﬂux in the present study
(assessed as total glutamine turnover) was 4.6 ± 0.6 nmoles/
min/mg protein for the control rats and 4.3 ± 0.5 nmoles/
min/mg protein for the gabapentin-treated rats (Table 1).
Dividing the glutamate/glutamine cycle ﬂux by total glu-
tamate turnover, kAA, provided an estimate of the fraction of
total glutamate metabolism that was used for neurotransmis-
sion, which was kBB/kAA ¼ 0.49 (see Table 1).
Effect of gabapentin on glutamate metabolism in the
retina
The conclusion that gabapentin is without effect on the rate
constant for glutamate turnover, the steady-state speciﬁc
radioactivity of glutamine and glutamate, and the calculated
rate of incorporation of H14CO3
– was surprising in view of
previous results that showed gabapentin reduces the steady-
state 14C-labeling of the glutamine and glutamate pool in ex
vivo rat retinas (Hutson et al. 2001; LaNoue et al. 2001;
Lieth et al. 2001). In these studies the ﬁrst-order rate
constant for glutamate turnover was not determined in the
presence of added gabapentin. Therefore, to determine
whether acute treatment of excised rat retinas with gabap-
entin inﬂuences the turnover rate of retinal glutamate, we
carried out kinetic analysis of [1)14C]glutamate disappear-
ance during the chase phase of a H14CO3
– pulse/chase
experiment. The natural log of intraretinal [1)14C]glutamate/
mg was plotted as a function of time (Fig. 4), based on
mathematical expressions analogous to (1). Calculated values
of kA for glutamate turnover were 0.097 ± 0.004/min for
control conditions and 0.096 ± 0.005/min for incubations
with 1 mM gabapentin (Table 2).
Although the ﬁrst-order rate constants of glutamate
turnover were similar, the results conﬁrmed that the steady-
state amounts of H14CO3
– incorporated into both glutamate
Table 1 Rate parameters of glutamate metabolism in whole brain in vivo
Parameter Control Gabapentin Description
kA (/min) [4)
13C]glutamate 0.066 ± 0.005 0.066 ± 0.005 First-order rate constant of [4)13C]glutamate turnover
kB (/min)
14C-glutamine 0.084 ± 0.010 0.084 ± 0.010 First-order rate constant of [1)14C]glutamine turnover
A* 14C-glutamate (nmoles H14CO3
–/mg protein) 9.79 ± 0.47 9.06 ± 0.40 Steady-state value of glutamate labeled with H14CO3
)
B* 14C-glutamine (nmoles H14CO3
–/mg protein) 8.80 ± 0.06 8.30 ± 0.30 Steady-state value of glutamine labeled with H14CO3
)
A glutamate mass (nmoles/mg protein) 142.2 ± 2.5 140.4 ± 2.1 Glutamate/mg protein
B glutamine mass (nmoles/mg protein) 54.9 ± 2.0 51.6 ± 1.3 Glutamine/mg protein
kA (A*) · 2 (nmoles H14CO3–/min/mg protein) 1.29 ± 0.11 1.20 ± 0.10 Flux of radiolabeled carbon into and out of glutamate
kB (B*) · 2 (nmoles H14CO3–/min/mg protein) 1.48 ± 0.17 1.39 ± 0.17 Flux of radiolabeled carbon into and out of glutamine
kA A (nmoles/min/mg protein) 9.39 ± 0.73 9.27 ± 0.72 Turnover of total glutamate in the brain
kB B (nmoles/min/mg protein) 4.61 ± 0.57 4.33 ± 0.53 Glutamate/glutamine cycle flux
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Fig. 3 The time course of changes in H14CO3
– incorporated into brain
glutamine (nmoles/mg) of control and gabapentin-treated rats. Con-
ditions are identical to those described in Fig. 1. Data points (means
± SEM) are shown as control (s) or gabapentin (d). The line drawn
represents the theoretical equation for first-order approach to a
steady-state value. Values shown are nmoles 14CO2 incorporated into
glutamine/mg protein.
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and glutamine and the mass amounts of glutamine were
reduced by gabapentin. The 14C label in glutamate was 14%
lower (p < 0.022) due to gabapentin and 38% lower in
glutamine (p < 0.005; Figs 5a and b and Table 2). The 23%
decrease in the mass of glutamine due to gabapentin is shown
in Fig. 5(d). Using the data illustrated in Figs 4 and 5 and
applying steady-state analyses described in Methods [e.g.
equations similar to (1) and in Lieth et al. 2001], glutamate
ﬂuxes with and without gabapentin were calculated
(Table 2). The de novo synthesis of 14C-glutamate was
decreased by 16% in the presence of gabapentin. The fraction
of glutamate disappearance that is due to neurotransmission
was 0.37, thus lower than the fraction used for neurotrans-
mission in the awake brain. Previous estimates (LaNoue
et al. 2001; Lieth et al. 2001) of the decline in de novo
synthesis of glutamate and glutamine were based on the
steady-state 14C content of glutamate plus glutamine, which
were consistently found to be 30% lower in the presence of
1 mM gabapentin. In this study, the same type of estimation
provides a value of 22%.
Discussion
The work described here was intended to provide a new
perspective with which to examine glutamate metabolism in
the awake, in vivo, mammalian brain. We reported a
preliminary study previously (Lieth et al. 2001) with
conclusions similar to those reported here. That study
showed H14CO3
– incorporation into glutamate at a single
time point only, so a kinetic analysis was not possible. By
collecting data at ﬁve time points and perfusing awake rats
simultaneously with [1)13C]glucose and H14CO3
–, it is
possible now to measure kinetic parameters and absolute
ﬂuxes. Thus, in this study of glucose and glutamate
metabolism in the brain, we measured 14C at different time
points and also analyzed incorporation of 13C into key
metabolites. 13C NMR has the unique ability to non-
invasively track labeled carbon and labeled nitrogen as they
pass through different metabolites and sequentially label
different atoms within the same molecule. Disadvantages
include lack of sensitivity and the complexity of the
information provided that must be deconvoluted by assump-
tion of speciﬁc models and by use of computer programs to
obtain clear cut values for metabolic ﬂuxes.
13C NMR was ﬁrst applied to the study of brain
metabolism in the 1980s and early 1990s by several
groups (Morris et al. 1985; Badar-Goffer et al. 1990;
Cerdan et al. 1990; Fitzpatrick et al. 1990), but recently
these studies have gained increased attention because of
the successful application of NMR techniques for the
measurement of global glutamatergic action in vivo (Aureli
et al. 1997; Lapidot and Gopher 1997; Sibson et al. 1997,
1998; Gruetter et al. 1998; Merle et al. 2002). Conclusions
drawn by these studies, however, have not been univer-
sally accepted. One issue has been the relationship
Table 2 Rate parameters of glutamate metabolism in excised rat retinas
Parameter Control Gabapentin Description
kA (/min)
14C-glutamate 0.097 ± 0.004 0.096 ± 0.005 First-order rate constant of [1)14C]glutamate turnover
kB (/min)
14C-glutamine 0.233 ± 0.021 0.319 ± 0.027 First-order rate constant of [1)14C]glutamine turnover
A* 14C-glutamate (nmoles H14CO3
–/mg protein) 1.19 ± 0.05 1.02 ± 0.03 Steady-state value of glutamate labeled with H14CO3
)
B* 14C-glutamine (nmoles H14CO3
–/mg protein) 0.511 ± 0.033 0.315 ± 0.016 Steady-state value of glutamine labeled with H14CO3
)
A glutamate mass (nmoles/mg protein) 49.84 ± 1.24 52.55 ± 1.07 Glutamate/mg protein
B glutamine mass (nmoles/mg protein) 7.61 ± 0.31 5.86 ± 0.19 Glutamine/mg protein
kA (A*) · 2 (nmoles H14CO3–/min/mg protein) 0.232 ± 0.012 0.196 ± 0.012 Flux of radiolabeled carbon into and out of glutamate
kB (B*) · 2 (nmoles H14CO3–/min/mg protein) 0.232 ± 0.012 0.196 ± 0.012 Flux of radiolabeled carbon into and out of glutamine
kA A (nmoles H
14CO3
–/min/mg protein) 4.83 ± 0.23 5.04 ± 0.28 Turnover of total glutamate in the retina
kB B (nmoles H
14CO3
–/min/mg protein) 1.77 ± 0.18 1.87 ± 0.17 Glutamate/glutamine cycle flux
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Fig. 4 The effect of gabapentin in the excised rat retina on the
washout of 14C from intraretinal 14C-glutamate (nmoles 14C-glutamate/
mg protein). Experimental conditions are described in Methods.
14C-glutamate values were transformed to natural log in order to
linearize the data. Data collected in control retinas (s) and data col-
lected in the presence of 1 mM gabapentin (d). The slope of the line
(ln/Dt) is equal to kA. Values shown are means of individual data points
where n ¼ 8.
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between ﬂux through the glutamine/glutamine cycle and
glucose utilization. Another has been the magnitude and
relative importance of the synthesis of glutamate de novo
from CO2 and pyruvate, which has been addressed in the
present study.
The measurement of anaplerotic ﬂuxes from pyruvate and
CO2 to glutamine is difﬁcult to assess with
13C-glucose and
values vary widely from 1% to 35% of total glutamine
synthesis (Shank et al. 1993; Aureli et al. 1997; Lapidot and
Gopher 1997; Sibson et al. 1997; Gruetter et al. 1998, 2001).
Some elegant studies have assessed glial metabolism, where
anaplerosis takes place, by using the glial-speciﬁc tracer, 13C-
acetate (Bluml et al. 2002; Lebon et al. 2002) and these
resulted in an estimate of glial citric acid cycle consistent
with earlier human studies (Gruetter et al. 2001). In the
modeling employed by Lebon et al. (2002), an upper limit
for anaplerotic synthesis of glutamate, relative to the
glutamate/glutamine cycle of 30% in human brain was
estimated. The data obtained in the Lebon study did not
permit a direct, absolute estimate of anaplerosis but rather
provided a value for the glial citric acid cycle ﬂux that
included anaplerosis.
Another method used for estimating anaplerosis involved
the measurement of the difference between [2)13C] and
[3)13C] isotopic enrichment in glutamine when [1)13C]glu-
cose was the substrate. This model made the assumption that
there is little or no equilibration between oxaloacetate (the
initial product of pyruvate carboxylase) and symmetrical
fumarate. Complete equilibration would equalize [2)13C] and
[3)13C] of glutamine making an estimate impossible. If
equilibration occurs but is incomplete, estimation of anaple-
rosis provides a lower limit. Some other studies usemodels that
provide a value for the ratio of PDH ﬂux to glial pyruvate
carboxylase – but do not estimate absolute values (Lapidot and
Gopher 1997; Grifﬁn et al. 2003).
The classical way to measure anaplerosis involves use
of radioisotopes (H14CO3
– or [1)14C]pyruvate) as sub-
strates (Heath and Rose 1985). The H14CO3
– subsequently
labels the C-1 of a-ketoglutarate and hence only the C-1
in glutamate and glutamine (see Figure 6). This label is
lost as 14CO2 when a-ketoglutarate is oxidized to succinate
and, thus, the amino acids glutamate and glutamine remain
labeled only at the C-1 position. This simpliﬁes the
analysis once the amino acids are separated chromato-
graphically. In fact, brain anaplerosis was estimated over
40 years ago by infusing H14CO3
– into cats and measuring
14C in glutamate, glutamine and aspartate, subsequently
isolated from the frozen brain tissue (Berl et al. 1962;
Waelsch et al. 1964). Although absolute rates were not
directly reported, the present data are in good agreement
with these early studies, as judged by a comparison of our
H14CO3
– incorporation into glutamate and glutamine with
theirs, at similar time points.
In order to measure anaplerosis directly we have used the
40 years old Waelsch et al. (1964) method, of perfusing
awake animals with H14CO3
– and separating metabolites
chromatographically to determine 14C incorporation. Incor-
poration of H14CO3
– into glutamate and glutamine was
measured by multiplying the ﬁrst-order rate constants of
amino acid turnover in these pools by the steady-state values
of H14CO3
– incorporated. The glutamate rate constant was
determined from the 13C entry kinetics. The glutamine rate
constant was derived directly from the 14C entry kinetics.
The method assumes that intervening metabolites (e.g.
between glucose and glutamate and between H14CO3
– and
glutamine) reach steady state quickly. The ﬂuxes calculated
in this way agree with some previous publications that have
employed 13C-glucose alone as substrate precursor (Gruetter
et al. 2001). It was also possible to use the data to calculate
ﬂux through the glutamate/glutamine cycle. Our data indicate
that about 50% of total glutamate turnover is used for
neurotransmission. This assumes that glutamate/glutamine
cycle ﬂux provides a measure of glutamatergic neurotrans-
mission.
The values we generate agree with the raw data of some
recent papers that use 13C NMR to evaluate glutamate
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Fig. 5 Effect of gabapentin on incorporation of H14CO3
– into gluta-
mate and glutamine in the retina at steady-state and their mass
amounts. Values shown are steady-state levels of 14C-glutamate (a)
and 14C-glutamine (b) after a 20 min ex vivo incubation of excised
retinas with 25 mM H14CO3
– prior to washout. Values are means ±
SEM, n ¼ 8. The p-value for 14C-glutamate is 0.022 and the p-value
for 14C-glutamine is 0.005. The mass (nmoles/mg protein) of unlabeled
glutamate (c) and glutamine (d) remained constant during the washout
phase of the experiment. Therefore values taken during the entire time
course were used to obtain the data shown. Values are means ± SEM,
n ¼ 32. The p-value for glutamine mass is 0.005. Control retinas (h)
and retinas incubated with 1 mM gabapentin (j).
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metabolism and its relationship to glucose consumption
(Sibson et al. 1998). The conclusion of those papers was that
glutamine/glutamate cycle ﬂux is approximately equimolar to
brain glucose consumption over a range of glutamatergic
activity. The precise relationship mentioned is: glucose
consumption ¼ 1.04 (glutamate/glutamine cycle ﬂux) + 0.1.
The assumptions made in drawing this conclusion were that
citric acid cycle ﬂux is twice the rate of glucose consump-
tion, that citric acid cycle ﬂux is equivalent to ﬂux through
a-ketoglutarate dehydrogenase, and that mitchondrial
a-ketoglutarate is in isotopic equilibrium with cytosolic
glutamate. Our raw data agree with the data of these workers
but, like some others (Yu et al. 1995; O’Donnell et al. 1998;
Grifﬁn et al. 2000; Gruetter et al. 2001; Attwell and Iadecola
2002; Choi et al. 2002; Garcia-Martin et al. 2002; Henry
et al. 2002; Chih and Roberts 2003), we are concerned about
the assumption of rapid isotopic equilibrium between a-
ketoglutarate and glutamate. The mitochondrial membrane
separates mitochondrial a-ketoglutarate from cytosolic glu-
tamate and mitochondrial translocases limit the rate of
exchange.
In generating absolute values for the rate of synthesis of
glutamate and glutamine from H14CO3
– in both the in vivo
brain and in the ex vivo retina, we assumed complete
equilibration of oxaloacetate and fumarate. The 14C-
oxaloacetate precursor of glutamate and glutamine there-
fore was assumed to be equally labeled in the 1 and 4
position. The [1)14C] is released as 14CO2 in the isocitrate
dehydrogenase reaction and therefore all 14C values were
multiplied by 2 in order to compensate for this loss. If
equilibration is not complete our values are overestimated,
at most by a factor of 2. The assumption of complete
equilibration has not been validated in the brain. The fact
that the [2)13C] and [3)13C] of glutamine were different
when brains were infused with [1)13C]glucose suggests
that there is not complete equilibration (Gruetter et al.
1998, 2001). However, other data from brain cells and
liver suggest that equilibration is substantial. In liver,
complete equilibration between oxaloacetate, malate, and
fumarate occurs catalyzed by the two reversible enzymes,
malate dehydrogenase, and fumarase (Sterniczuk et al.
1991). Evidence in favor of signiﬁcant equilibration in the
CNS is appearance of 14C-pyruvate when incubating
retinas (Lieth et al. 2001) or cultured astrocytes with
H14CO3
– (Gamberino et al. 1997). H14CO3
– is incorpor-
ated initially into the 4-position of oxaloacetate. Decarb-
oxylation by malic enzyme or by phosphoenolpyruvate
carboxykinase to form pyruvate removes carbon at the 4
position. Therefore, no label would appear in pyruvate or
in the middle carboxyl group of isocitrate without
equilibration with symmetrical fumarate (Fig. 6). In
primary cultures of rat brain astrocytes incubated with
H14CO3
–, pyruvate was the most heavily labeled 14C
product (Gamberino et al. 1997), whereas in the retina it
was the second most heavily labeled 14C product (Lieth
et al. 2001). To simplify calculations, most NMR models
do not account for any equilibration (Gruetter et al. 2001).
The assumptions made by various laboratories have been
discussed in a recent publication (Merle et al. 2002). It
will be important to determine the precise degree of
equilibration at the fumarase step and whether it is
inﬂuenced by metabolic state.
Rates of synthesis of glutamate and glutamine from
H14CO3
– measured here likely reﬂect only a fraction of
total brain CO2 ﬁxation. The total rate of pyruvate
carboxylation is probably higher than the anaplerotic
synthesis of glutamate and glutamine. For example, a
fraction of the 14C-oxalacetate synthesized can be metabo-
lized by phosphoenolpyruvate carboxykinase (PEPCK) or
malic enzyme to regenerate CO2 and pyruvate, leading to
pyruvate cycling at the cost of one ATP/pyruvate (Cerdan
et al. 1990). Likewise, some 14C-a-ketoglutarate formed
via pyruvate carboxylase will not be converted to glutam-
ate and glutamine but will continue around the citric acid
cycle (losing its C-14 label) and the excess malate
produced will be converted to pyruvate and CO2 by malic
enzyme or PEPCK. This represents a substantial fraction of
total CO2 ﬁxation in agreement with previous studies
(Gruetter et al. 1998, 2001; Sibson et al. 2001). Conver-
sion of glutamate to pyruvate and lactate by cultured
neonatal astrocytes has also been monitored (Sonnewald
et al. 1993; Hutson et al. 1998). Conversion of 14C-
glutamate and of H14CO3
– to 14C-pyruvate (pyruvate
cycling) occurs in retinas (Lieth et al. 2000, 2001).
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Another goal of the present study was to evaluate the
ability of the neuroactive drug gabapentin to slow the
synthesis of glutamate and perhaps neurotransmission.
Gabapentin is an antiseizure drug, also used to alleviate
chronic pain. We have published reports previously demon-
strating its ability to block de novo synthesis of glutamate,
possibly by limiting the supply of branched chain amino acid
for synthesis of glutamate. Others proposed that gabapentin
acts by inhibiting both branched chain aminotransferases
(BCATc and BCATm; Goldlust et al. 1995; Welty et al.
1995), but our studies showed that gabapentin is a speciﬁc
inhibitor of the cytosolic branched chain aminotransferase
(Hutson et al. 1998; Lieth et al. 2001).
No signiﬁcant effect of gabapentin was detected in the
present study of whole brain although its effect was evident
in the retina (Lieth et al. 2001). Errante and Petroff (2003)
also studied the inﬂuence of gabapentin on whole-brain
metabolism. They used the same amount of gabapentin that
we did (100 mg/kg) and observed a small but signiﬁcant
decline in glutamate mass (p < 0.05, n ¼ 26 rats), 2 h after
an i.p. injection. We observed declines in 14C-glutamate and
14C-glutamine of similar magnitude but the declines were not
signiﬁcant. Our previous reports of inhibition of de novo
synthesis by gabapentin in retinas were based on measure-
ments of steady-state values of 14C-glutamate and 14C-
glutamine. We re-examined the conclusion in the present
study by carrying out a full kinetic analysis which conﬁrmed
the previous results.
The ability to quantitate anaplerosis and neuronal gluta-
mate turnover simultaneously, demonstrated here, sets the
stage for studies of neuroactive drugs on glutamate/pyruvate
cycling. Thus, one can evaluate the possibility that drugs
such as gabapentin (Su et al. 1995; Bergey et al. 1997;
Hutson et al. 1998; Rowbotham et al. 1998) and acetazol-
amide (Dodgson et al. 2000) and diets such as the ketogenic
diet (Nordli 2002), all of which ameliorate epilepsy might
exert their inﬂuence on neurotransmission by altering the
anaplerotic ﬂow of carbon from pyruvate carboxylase to
glutamate. Acetazolamide inhibits pyruvate carboxylase
(Hazen et al. 1997) and gabapentin inhibits the conversion
of astrocytic a-ketoglutarate to glutamate by blocking
branched chain amino acid access to the branched chain
aminotransferase and possibly by inhibiting the branched
chain amino acid cycle via inhibition of the cytosolic
branched chain aminotransferase (Hutson et al. 1998; Lieth
et al. 2001).
In conclusion, the astrocytic pyruvate/glutamate cycle is a
quantitatively important component of glutamate metabolism
in brain and retina. Because the 14C method has sufﬁcient
sensitivity it can be employed in future in vivo studies to
examine the effects of dietary manipulations and drugs on
speciﬁc regions of the brain, possibly by dissecting these
regions, after whole animal perfusions with 13C- and 14C-
labeled metabolites.
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Appendix
From standard equations of label incorporation and efﬂux,
such as Equation 1 in Gruetter et al. (1998), relationships
between the label incorporation into metabolites and
metabolic ﬂuxes can be derived. Restating Equation 1 from
Gruetter et al. (1998) in a simpliﬁed form, where Vout is
equal to the sum of all ﬂuxes by which label leaves the pool
P, gives
d13P
dt
ðtÞ ¼
Xn
i¼1
Vi
13SiðtÞ
Si
 Vout
13PðtÞ
P
ðA1Þ
For the present study and derivation of the analytical form of
(1) it shall be assumed that the precursor pool labels
instantaneously at t ¼ 0:
13SiðtÞ
Si
¼ ai for t > 0 ðA2Þ
where ai is the steady-state isotopic enrichment of the
precursor Si. A general solution for (A1) shall be attempted
with
13P(t) ¼13 P1 þ A0ekt ðA3Þ
where 13P¥ represents the amount of steady-state labeling of
the Product P. Taking the derivative with respect to time t
gives
d13P
dt
ðtÞ ¼ kA0ekt ðA4Þ
Conversely, substituting equations (A2) and (A3) into (A1)
results in
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d13P
dt
ðtÞ ¼
Xn
i¼1
Viai  Vout
13P1 þ A0ekt
P
ðA5Þ
Equating the right hand side of (A4) and (A5) results in the
following relationships:
13P1
P
¼
Pn
i¼1
Viai
Vout
ðA6Þ
and
k ¼ Vout
P
ðA7Þ
with the starting condition 13P(0) ¼ 0 resulting in
A0 ¼ 13P1 ¼ P
Pn
i¼1
Viai
Vout
ðA8Þ
when substituting (A6).
From (A6) it follows that if only one precursor Sj is
labeled, we can calculate the ﬂux from that precursor to the
product, as follows: Assume ai ¼ 0 for i „ j, and substituting
(A7) into (A6), results in
Vj ¼ k
13P1
aj
ðA9Þ
The nomenclature for 14C labeling is derived from these
equations by replacing the superscript 13 with *. In the paper,
A and B represent the product pool size P (mass) of
glutamate and glutamine, respectively.
In this case, knowing the relative precursor isotopic
enrichment (A2), aj, and the steady-state labeling of the
product, as well as the product turnover time, the speciﬁc
ﬂux Vj can be calculated. In practice, aj is the most difﬁcult
parameter to deﬁne experimentally. For example, in the
present study aj is unknown for the anaplerotic ﬁxation of
CO2, because the labeling of the amino acids is diluted by
labeling from the glial TCA cycle (due to acetyl-CoA
oxidation in astrocytes) and from the lower enrichment of
neuronal glutamate by the action of the glutamate/glutamine
cycle. In this and similar cases, however, assuming the
precursor enrichment, e.g. that of plasma H14CO3
–, can be
used for obtaining lower bounds of the estimated ﬂux, the
calculation is possible. To correct for the dilution of the TCA
cycle intermediates by oxidation of glucose and other energy
substrates, dilution of the H14CO3
– labeling of the glial
citrate pool, which occurs at the rate Vg (Gruetter et al.
2001), this apparent anaplerotic ﬂux has to be multiplied by
[1 + Vg/VPC]. Interestingly, as glutamine cannot be labeled
more than fully by H14CO3
–, the relative enrichment of
glutamine B*/B (normalized relative to that of H14CO3
–,
Table 1) provides an upper limit for Vg/VPC: Vg/VPC < B/
B*-1. Another correction factor needs to deal with the
dilution from neuronal glutamate, which further indicates
that the present ﬂuxes for anaplerosis underestimate the true
rate of anaplerosis.
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